An established principle in oncology is that cancer is a disease that is initiated and maintained by somatic alterations in the genome. Recent advances in DNA-sequencing technologies have reaffirmed this principle and have greatly facilitated the molecular understanding of the genetic basis for various malignancies 1 . The prevailing challenge is to decipher how these genomic alterations culminate in malignant transformation and how they can be targeted for therapeutic gain. A central theme emerging from the cancer genome data is recurrent mutations in epigenetic regulators 2 . It is now apparent that mutations and/or translocations of epigenetic regulators are some of the most prevalent abnormalities observed in hematopoietic malignancies 3, 4 . The realization that epigenetic regulators are widely implicated in the initiation and maintenance of cancer has fueled substantial interest in identifying targeted therapies that alter malignant transcription programs and offer new opportunities for therapeutic intervention in these malignancies. Importantly, several new epigenetic therapies have now transitioned into the clinical arena, where they are being assessed in a range of tumors 2, 5, 6 . Although combination therapy is the cornerstone of cancer management and is also the future for emerging epigenetic therapies, several lines of evidence caution against an empirical approach to combination epigenetic therapy. Without a sound molecular basis, additional benefits are often not conferred by these combinations, and in some cases the combination of epigenetic therapies results in substantial functional antagonism [7] [8] [9] . Therefore, preferred combinations should be guided by a thorough preclinical evaluation based on a comprehensive understanding of the molecular pathogenesis of the disease.
a r t i c l e s
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The mixed lineage leukemia (MLL; official symbol KMT2A) gene encodes a histone methyltransferase that plays an integral role in normal embryogenesis and the maintenance of both fetal and adult hematopoiesis [10] [11] [12] . Importantly, chromosomal translocations involving this essential epigenetic regulator account for over 70% of infantile leukemia and up to 10% of adult leukemia 13 . These MLL-translocated leukemias follow an aggressive clinical course with a poor response to conventional treatment, thus highlighting the urgent need for better therapies in this group of diseases 13 . The poor prognosis conferred by MLL fusion protein (MLL-FP) leukemia has attracted substantial research attention with the aim of studying transcriptional dysregulation a r t i c l e s to identify new therapeutic opportunities 13 . Thus far, several small molecules have been developed to target various components of the transcription machinery coopted by MLL-FP [14] [15] [16] [17] . Many of these targeted therapies have shown preclinical promise and are currently being evaluated in clinical trials. Despite this progress, understanding of the molecular events that govern leukemogenic transcription programs driven by MLL-FP remains incomplete.
Over 60 different MLL-translocation partners have been identified, many of which are members of multisubunit protein complexes that regulate transcription. Indeed, a fundamental abnormality in transcriptional elongation appears to underpin the molecular pathogenesis of MLL-translocated leukemias 18 . Recent studies have suggested that the functional integrity of two major protein complexes-the super elongation complex (SEC) and the disruptor of telomeric silencing complex (DOT1Lc)-is critical for malignant transformation by MLL-FP 18 . Although there is a general consensus that the various members of these complexes play an integral role in the pathogenesis of MLL-FP leukemia, there is substantial ambiguity related to the composition of these complexes and the mechanisms of transformation.
We set out to determine whether BRD4 and DOT1L are in separate nuclear complexes and whether they function in a mutually exclusive manner in regulating the malignant transcription programs that underpin MLL-FP leukemia. Together our findings established that BRD4 and DOT1L mainly reside in distinct protein complexes. Although these separate complexes regulate discrete transcription programs in MLL-FP leukemia, there is a high level of cooperation and interdependency at a subset of genes, which are in proximity to superenhancers and are critical to the molecular pathogenesis of MLL-FP leukemia. At these loci, we found that DOT1L, via dimethylated histone H3 K79 (H3K79me2), facilitates the recruitment of EP300; EP300 acetylates histone H4, which in turn regulates the binding of BRD4 to chromatin and the subsequent transcriptional output of these genes. Dual targeting of these essential transcriptional regulators leads to a profound suppression of transcription at these genes, which are important to the maintenance of MLL-FP leukemia, thus providing a molecular rationale for future combination therapies.
RESULTS

BRD4 and DOT1L are in distinct macromolecular complexes
Previous studies have established that the functional integrity of the transcription elongation complexes containing BRD4 or DOT1L is critical to the initiation and maintenance of MLL-FP leukemia 14, [19] [20] [21] [22] [23] [24] [25] . Nonetheless, a major unresolved point of contention is whether BRD4 and its associated positive transcription elongation factor b complex (PTEFb), composed of cyclin T1-cyclin T2 and cyclin-dependent kinase 9 (CDK9), are in shared or separate complexes with the histone methyltransferase DOT1L. Methodological differences are likely to have contributed to this controversy, because virtually all of the studies performed to date have used either transient or stable expression of epitope-tagged proteins for biochemical and proteomic analyses [19] [20] [21] [22] [23] [24] [25] . We initially sought to address this issue by using quantitative mass spectrometry and specific antibodies against endogenous proteins. Our data clearly demonstrated that BRD4 associates with CDK9 as part of the PTEFb and with other members of the previously identified superelongation complex (SEC) 21, 25 . Importantly our data suggested that BRD4 and PTEFb are found separately from DOT1L in various hematopoietic cells that contain wild-type MLL or those that also contain an MLL-FP (Fig. 1a,b and Supplementary Fig. 1a ). These findings were further supported by size-exclusion chromatography analyses of the native protein complexes ( Fig. 1c and Supplementary  Fig. 1b ) and suggested mutual exclusivity of complexes containing BRD4-CDK9 and DOT1L. Notably, MLLT1 which has previously been used to copurify DOT1L and CDK9 (ref. 23 ) was the only component shared between the otherwise distinct protein complexes containing BRD4 and DOT1L.
A major advantage of using specific small molecules that target a domain of a protein within a macromolecular complex is that they can engage and negate the functional activity of the protein while mostly preserving the native composition of the protein complex. We have previously used this beneficial property to perform chemoproteomics identifying native BRD4 as part of the PTEFb-SEC complex 14 . To extend these data further, we fully characterized the specificity of the DOT1L inhibitor SGC0946 (ref. Table 1 ) and functionalized it so that it could be used as an affinity matrix to purify DOT1L and its associated complex members (Supplementary Fig. 2a,b) . We analyzed these interactions via a chemoproteomic competition binding assay ( Fig. 1d and Supplementary Fig. 2c) . Together, our chemoproteomic data verified the high specificity of these inhibitors and highlighted their utility as molecular probes to interrogate the function of endogenous BRD4 and DOT1L. These data also confirmed that DOT1L and BRD4 exist in separate protein complexes, albeit with some shared components, such as MLLT1 (Fig. 1e) .
Targeting BRD4 and DOT1L results in synergy in MLL leukemia
Having established that BRD4 and DOT1L are components of two distinct protein complexes, we next sought to understand whether targeting both of these transcriptional regulators offered any therapeutic advantage. MLL-FP leukemia cells have previously been shown to be the most responsive molecular subtype to either DOT1L or BET-inhibitor therapy; however, the kinetics by which BRD4 and DOT1L inhibition exert their therapeutic effects in MLL-FP leukemia is markedly different 14, 15, 27 . Therefore, to assess the potential benefit of combination therapy, we first established the maximum ineffective dose of I-BET and SGC0946 in various human and mouse leukemia cell lines (Supplementary Fig. 2d ,e and data not shown). Using these concentrations, we demonstrated that combination exposure to I-BET and SGC0946 resulted in marked synergistic effects that were specific to MLL-FP mouse and human leukemia cell lines (Fig. 2a-d and Supplementary Figs. 2f-h and 3a-d) . Importantly, we also confirmed the synergistic activity in clonogenic assays with several primary human AML samples containing various MLL translocations (Fig. 2e) .
Although in vivo delivery of the preclinical BET-bromodomain inhibitors has been relatively straightforward 14 , the pharmacokinetic properties of the preclinical DOT1L inhibitor EPZ000477 (closely related to SGC0946) has posed significant challenges to in vivo studies necessitating either ex vivo pretreatment of leukemia cells 28 or administration via an implantable subcutaneous osmotic minipump 15 . We therefore characterized the pharmacokinetic properties of SGC0946 as a single agent or in combination with I-BET therapy in vivo (Supplementary Fig. 3e,f) . Using the optimal delivery strategy, we investigated the therapeutic potential of the combination in a mouse model of aggressive MLL-AF9 leukemia. Consistently with our in vitro and ex vivo studies, these data showed that whereas subtherapeutic doses of I-BET or SGC0946 offered no survival advantage, combination therapy significantly prolonged survival and reduced disease burden (Fig. 3a,b and Supplementary Fig. 3g ).
Previous studies have also used genetic manipulation of BRD4 (refs. 27,29) or DOT1L 29, 30 to demonstrate their individual role as therapeutic targets in MLL-FP leukemia. Using our previously validated inducible short hairpin RNAs (shRNAs) against BRD4 (ref. 31) , together with inducible hairpins targeting DOT1L, we replicated these findings. Moreover, we showed that combined knockdown of BRD4 and DOT1L had a more potent influence on proliferation in vitro ( Fig. 3c and Supplementary Fig. 4 ), in agreement with our data using I-BET and SGC0946. To further extend these findings, we performed in vivo competition assays to read out the leukemogenic potential of the shRNA-expressing cells. To do this, we used a strategy allowing the reliable assessment of the number of shRNA-expressing cells at all times during the experiment, including the time when the mouse succumbs to the disease. After transplanting an equal number of shRNA-expressing cells, we found at multiple time points throughout the experiment, including the time of death, that the number of shRNA-expressing cells present in all compartments (peripheral blood, spleen and bone marrow) was lowest in the mice transplanted with cells expressing shRNA against both BRD4 and DOT1L (Fig. 3d-f ). Importantly, these data were entirely consistent with our data using small molecules targeting DOT1L and BRD4, and they provide compelling preclinical evidence that dual targeting of BRD4 and DOT1L provides significantly greater efficacy in MLL-FP leukemia.
BRD4 and DOT1L co-regulate a subset of genes in MLL leukemia
To understand the molecular basis for the observed functional synergy, we next sought to investigate the transcription programs regulated by BRD4 and DOT1L. The transcriptional changes following DOT1L or BET inhibition in MV4;11 cells have previously been studied 14, 15 , and our findings were highly correlated with the results of these previous studies at identical time points (Supplementary Fig. 5a ).
In agreement with our proteomic and biochemical data, BRD4 and DOT1L generally controlled distinct gene expression programs (Fig. 4a) . Interestingly, we found that dual targeting of BRD4 and DOT1L resulted in a more extensive and distinct alteration in gene expression, thus raising the possibility of a functional interdependency of these two discrete transcriptional complexes ( Fig. 4a and Supplementary  Fig. 5b ). To address this possibility and to better understand the molecular events at chromatin, we performed ChIP-seq analyses after I-BET and/or SGC0946 treatment for BRD4 binding, RNA polymerase II (POL II) occupancy and density of H3K79me2, a histone modification deposited exclusively by DOT1L 32 . These data identified three major subsets of genes regulated by the DOT1L-and BRD4-containing complexes: (i) a subset in which H3K79me2 was decreased by DOT1L inhibition, but BRD4 binding was either absent or unaffected with I-BET treatment; (ii) a subset of genes in which BRD4 binding was decreased by BET inhibition, but H3K79me2 was either absent or unaffected within this time frame by SGC0946 treatment; and notably (iii) a subset of genes that are co-regulated by both BRD4 and DOT1L ( Fig. 4b and Supplementary Table 2) . The genes co-regulated by BRD4 and DOT1L inhibition correlated highly with genes that were downregulated by combination therapy in our RNA-seq data (Fig. 4c) . Importantly, these genes were also highly correlated with genes that have been shown to be directly bound by MLL-FP 30 (Fig. 4d) , and geneGO analysis further highlighted that these genes are also critically involved in normal and malignant hematopoiesis (Supplementary Fig. 5c ).
To further study the effects of BRD4 and/or DOT1L inhibition on transcriptional output in these three subsets of genes, we compared our RNA-seq and POL II occupancy data with changes in BRD4 displacement and/or a decrease in H3K79me2 ( Fig. 4e and  Supplementary Fig. 5d ). These data demonstrated several important findings. First, BRD4 displacement from chromatin led to a greater alteration in transcriptional output than a decrease in H3K79me2 (Fig. 4e,f and Supplementary Fig. 5d-e) . As previously reported, we found that H3K79me2 was an excellent marker of actively transcribed genes 32 (Fig. 5a) ; however, our data suggested that H3K79me2, by itself, was not required to maintain transcriptional activity at most genes ( Fig. 4e and Supplementary Fig. 5d,e) . Importantly, these data also highlight that dual inhibition of BRD4 and DOT1L results in a dramatic suppression of transcription that is especially notable at the co-regulated genes (Fig. 4e,f and Supplementary Fig. 5d ).
H3K79me2 regulates the binding of BRD4 to chromatin
We next sought to understand the distinguishing features of the subset of genes that were co-regulated by BRD4 and DOT1L. By assessing POL II occupancy across the coding region of the subset of genes that were regulated by inhibition of BRD4 and/or DOT1L, we found that the co-regulated genes were the most transcriptionally active subset (Fig. 5a) . Highly transcribed genes regulated by BRD4 have recently been associated with superenhancers 33 , and our findings were consistent with this observation. Notably, however, we further refined these previous observations by demonstrating that the genes that are co-regulated by BRD4 and DOT1L in MLL-FP leukemia are in fact the subset of genes most proximal to a superenhancer (Fig. 5b) . Although it has clearly been established that superenhancers have multiple features distinct from those of typical enhancers, including a greater occupancy Fig. 6a ) and an increased sensitivity to BET-bromodomain inhibitors 33 , the regulatory framework governing these intriguing cis-regulatory elements and their associated genes is not fully understood 34 .
The histone modification H3K79me2 is most commonly found throughout the gene bodies of actively transcribed genes 32 . Interestingly, we found that H3K79me2 was also markedly enriched at transcriptionally active superenhancers compared with typical enhancers (Fig. 5c,d and Supplementary Fig. 6b ). Importantly, we detected increased levels of H3K79me2 at superenhancers regardless of whether the superenhancer was an intragenic or intergenic regulatory element (data not shown). Although BET inhibition did not lead to a decrease in H3K79me2 levels ( Supplementary Fig. 6c ), we unexpectedly observed that inhibition of DOT1L resulted in a marked decrease in the binding of BRD4 at superenhancers (Fig. 5e) and their associated genes in human MLL-AF4-and MLL-AF9-driven cells (Supplementary Fig. 6c,e) . Importantly, dual inhibition resulted in a near-complete loss of BRD4 and a dramatic suppression of transcription at these sites ( Fig. 5e and Supplementary Fig. 6c,d ). These intriguing data suggested an unrecognized functional interplay between BRD4 and DOT1L. In further support of this contention, our genome-wide data highlighted the specificity of this functional relationship by demonstrating that, although I-BET resulted in displacement of BRD4 from chromatin regardless of the presence or absence of H3K79me2, DOT1L inhibition resulted in BRD4 displacement only at genomic regions where H3K79me2 and BRD4 binding were colocated (Fig. 5f) .
DOT1L has recently been shown to methylate nonhistone proteins 35 ; we therefore sought to understand whether DOT1L's regulation of BRD4 binding at chromatin occurs through H3K79 methylation. To address this question, we made use of SGC0946's remarkably long residence time 26 . This feature, coupled with the slow turnover of H3K79me2 ( Supplementary Fig. 1d and Supplementary Fig. 7a,b) , enabled washout experiments to discriminate the potential immediate effects of DOT1L inhibition, with unaltered H3K79me2, from the effects mediated by decreased H3K79me2 in the absence of sustained DOT1L inhibition (Supplementary Fig. 7 ). These data clearly showed that DOT1L inhibition, in the absence of decreased H3K79me2, did not alter BRD4 binding (Fig. 5g and Supplementary Fig. 7h) . In contrast, when H3K79me2 levels were decreased after SGC0946 npg a r t i c l e s washout, we observed a striking decrease in BRD4 chromatin occupancy at superenhancers and the genes with overlapping BRD4 and H3K79me2 ( Fig. 5g and Supplementary Fig. 7h) . Together, these data demonstrated a functional reciprocity between these two transcriptional regulators that is mediated via H3K79me2.
H3K79me2 facilitates histone H4 acetylation and BRD4 binding
To understand the molecular mechanism underpinning this functional interdependency, we concentrated our efforts on the genes cooccupied by H3K79me2 and BRD4, whose expression was decreased by DOT1L inhibition. We observed that the majority of genes whose expression a r t i c l e s decreased after a reduction in H3K79me2 also had an accompanying loss of BRD4 binding (Supplementary Fig. 8a ). To decipher whether this loss of BRD4 binding was required for the transcriptional output of these genes, we knocked down BRD4 in human MLL-AF4-and MLL-AF9-driven cells, and assessed transcription at these sites. These data demonstrated that decreased BRD4 levels mimicked the effects of DOT1L inhibition at these genes (Fig. 6a,b and Supplementary  Fig. 8b ). Importantly, these data also provided directionality for the sequence of events, because the decrease in BRD4 resulted in a change in gene expression without altering H3K79me2 levels (Fig. 6c) , thus suggesting that BRD4 binding is downstream of H3K79me2 and is directly responsible for modulating gene expression at these loci. To address the mechanism linking H3K79me2 with chromatinbound BRD4, we first sought to understand whether BRD4 is capable of directly binding H3K79me2. Using histone tail peptides that were unmethylated or mono-, di-or trimethylated at H3K79, we performed immunoprecipitation experiments on nuclear extracts, and assessed the purified fraction by quantitative mass spectrometry. These data showed that BRD4 did not directly bind methylated H3K79 (Supplementary Fig. 8c ). It has previously been established that BRD4 is most avidly associated with chromatin through binding acetylated lysines primarily on the tail of histone H4, and recent data have demonstrated that acetylated histone H4 K5 (H4K5ac) is the modification that is most influential in regulating the avidity of BRD4 for chromatin 36, 37 . An established principle in chromatin biology is histone cross-talk, wherein the presence or absence of a histone modification facilitates the deposition or removal of another histone modification 38 . We therefore assessed the possibility that H3K79me2, via histone cross-talk, influences the deposition of H4K5ac at these loci. Remarkably, we found that after DOT1L inhibition, the decreased levels of H3K79me2 led to a concomitant decrease in H4K5ac. These changes were accompanied by decreased BRD4 binding and transcription of the associated genes ( Fig. 6d and Supplementary  Fig. 8a,d,e) . Importantly, this mode of histone cross-talk was also highly specific and was confined to regions of the genome where H3K79me2 and H4K5ac overlapped with BRD4 binding (Fig. 6e,f and Supplementary Fig. 8a,f) .
To explore the underlying basis for the specific regulation of H4K5ac by H3K79me2, we asked which transcription factor binding sites are most significantly enriched at the areas where H3K79me2 regulates H4K5ac. Notably, the major transcription-factor-binding site enriched in this location was CREB1 (Fig. 7a) . Importantly, we confirmed that CREB1 was indeed bound at a number of genes for which H3K79me2 influences the deposition of H4K5ac and also found that the binding of CREB1 at these loci was regulated by DOT1L-mediated H3K79 dimethylation (Fig. 7b) . Furthermore, knockdown of CREB1 by two independent and specific shRNAs mimicked the effects of DOT1L and BRD4 inhibition at these genes ( Fig. 7c and Supplementary Fig. 8g) . Together, these data suggested that H3K79me2 facilitates the DNA binding of transcription factors such as CREB1 at genes that are co-regulated by BRD4 and DOT1L. CREB1 not only plays a role in normal and malignant hematopoiesis 39 but crucially also recruits CREBBP and EP300, which are histone acetyltransferases capable of acetylating histone H4 K5 and K8 (refs. 40,41) .
In agreement with the possibility that CREB1 recruits EP300, which in turn acetylates H4 K5, we found that EP300 was bound at the same sites as CREB1, and moreover its recruitment, like that of CREB1, was dependent on DOT1L-mediated H3 K79 dimethylation (Fig. 7d) . In further support of our data, we and others found that knockdown or small-molecule inhibition of the catalytic activity of EP300 is highly correlated with the transcriptional effects of inhibiting BRD4 chromatin occupancy 41 (Fig. 7e) . Together, these data support a model in which DOT1L methylates histone H3K79, thus leading to a more permissive chromatin environment for the binding of CREB1 and subsequent recruitment of EP300, which in turn acetylates histone H4 K5 and enables the binding of BRD4, thereby potentiating gene expression at several critical MLL-FP-driven oncogenes (Fig. 8) .
DISCUSSION
It is increasingly becoming apparent that a fundamental imbalance in the epigenetic regulation of transcription underpins the molecular npg a r t i c l e s pathogenesis of many cancers including acute leukemia. MLL-fusion proteins are powerful oncogenes, and these leukemias have few other genomic aberrations 42 . The poor prognosis of these leukemias and their relatively simple genetic background have provided the best model for understanding the influence of epigenetic regulators on malignant transcription programs. These studies have yielded several new epigenetic therapies that are now being investigated across a broad range of malignancies [14] [15] [16] [17] . Our clinical experience has highlighted that monotherapy is very unlikely to offer sustained benefits in the management of aggressive malignancies such as MLL-FP leukemia. It has also highlighted the pitfalls of a largely empirical approach to combination therapies, especially when these involve the manipulation of context-dependent epigenetic regulators 8, 9 . Therefore, future combination therapies should be based on a comprehensive molecular rationale. It has been well established through genetic experiments in sophisticated mouse models that DOT1L has an integral role in MLL-FP leukemia 30, 43, 44 . Although H3K79me2 has also clearly been demonstrated to be associated with active transcription, what remains uncertain is whether this histone modification is required to maintain the transcriptional activity of these genes. Many histone modifications may simply alter the local chromatin environment or recruit specific factors to chromatin but have little direct effect on transcription 45 . Our data suggest that H3K79me2 is an excellent marker of actively transcribed genes; however, DOT1L inhibition leads to a profound decrease in H3K79me2 without a significant change in POL II occupancy or transcription, as measured by RNA-seq, thus suggesting that H3K79me2 is not required to directly maintain transcription at the majority of these genes. It has recently been demonstrated that H3K79me2 helps maintain an open chromatin state by inhibiting the chromatin localization of the transcriptional repressors SIRT1 and SUV39H1 (ref. 28) , and, in agreement with these findings, our results suggest that H3K79me2 provides a permissive chromatin state for the recruitment of transcription factors and transcriptional coactivators. Although we found that H3K79me2 facilitates the binding of CREB1 and EP300, the latter of which acetylates histone H4 and facilitates BRD4 localization, it is also possible that other transcription factors and/or histone acetyltransferases might be recruited to perform analogous functions. Indeed, a recent report has shown that other hematopoietic transcription factors in association with EP300 may also localize BRD4, thereby potentiating transcription 41 .
Although the effects of inhibition of BRD4 and DOT1L have generally been best characterized in the MLL-FP leukemias, emerging evidence suggests that therapies against these targets may play a role in other molecular subsets of acute leukemia and indeed other malignancies [46] [47] [48] [49] . The differential sensitivity to these therapies in other cancers is presumably the result of intrinsic differences in the molecular pathogenesis of these diseases as well as the existence of several other protein complexes that lack DOT1L or BRD4 and affect or regulate malignant transcription programs initiated by non-MLL-FP oncogenes 50, 51 . Nevertheless, although our study focused on MLL-FP leukemia, the mechanism described here might have broader applications in other malignancies and/or normal tissues.
These data also have an immediate clinical relevance, because therapeutic responses to either BET inhibitors 52 or DOT1L inhibitors 53 as single agents have been reported in early clinical trials. Because MLL-FP leukemias remain a disease in urgent need for new therapeutic options, our findings emphasize that targeting of BRD4 and DOT1L in combination negates any functional compensation between these two discrete yet interdependent transcription complexes. Our results provide a unifying mechanism that accounts for the exquisite sensitivity of MLL-FP leukemia to DOT1L-and BRD4-targeted therapies and specify a molecular framework for future combination epigenetic therapies in the clinical arena.
METHODS
Methods and any associated references are available in the online version of the paper. 
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Reprints and permissions information is available online at http://www.nature.com/ reprints/index.html. Size-exclusion chromatography. Cell lysates were separated on a Superose-6 column, and fractions were analyzed by western blotting to detect the presence of proteins of interest.
Chemoproteomics. HL-60 nuclear extracts were prepared, and immunoprecipitations of BRD4 and DOT1L were performed as previously described 14 . Briefly, antibodies (anti-BRD4 (ref. 14), anti-DOT1L (Novus Biologicals NB100-40845) and a control rabbit IgG (Sigma 15006) were covalently coupled to 100 ìl AminoLink resin (Thermo Fisher Scientific 20501). The immobilized antibodies were incubated with HL-60 nuclear extracts for 3 h, with rotation at 4 °C. Beads were washed, and protein was recovered for LC-MS/MS analysis. Antibody validation is provided on the manufacturers' websites. Affinity matrices were generated, and affinity profiling assays were performed with HL-60 nuclear extracts, as described previously 14 . Beads were derivatized with 20 µM GSK2691981, an analog of GSK1210151, or 1 mM GSK3338813A, an analog of SGC0946 (chemical synthesis of GSK3338813A is described in the Supplementary Note).
LC-MS/MS analysis. Sample preparation, labeling with isobaric mass tags, peptide fractionation and MS analyses were performed essentially as previously described 54, 55 . All experiments (except BRD4 IP) were performed with the TMT (Thermo-Fisher Scientific) multiplex option to allow comparison of up to ten conditions in one analysis 56 .
Peptide and protein identification. Mascot 2.4 (Matrix Science) was used for protein identification with a 10 p.p.m. mass tolerance for peptide precursors and 20 mDa (HCD) mass tolerance for fragment ions. Carbamidomethylation of cysteine residues and TMT modification of lysine residues were set as fixed modifications, and methionine oxidation, N-terminal acetylation of proteins and TMT modification of peptide N termini were set as variable modifications. The search database consisted of a customized version of the International Protein Index protein sequence database combined with a decoy version of this database created with a script supplied by Matrix Science. Unless stated otherwise, we accepted protein identifications as follows: (i) For single spectrum-to-sequence assignments, we required this assignment to be the best match and a minimum Mascot score of 31 and a 10× difference of this assignment over the next best assignment. On the basis of these criteria, the decoy search results indicated <1% false discovery rate (FDR). (ii) For multiple spectrum-to-sequence assignments with the same parameters, the decoy search results indicated <0.1% FDR. All identified proteins were quantified; the FDR for quantified proteins was <1%.
Peptide and protein quantification. Reporter-ion intensities were read from raw data and multiplied with ion accumulation times (in units of milliseconds) to yield a measure proportional to the number of ions; this measure is referred to as ion area 57 . Spectra matches to peptides were filtered according to the following criteria: mascot ion score >15, signal-to-background of the precursor ion >4 and signal-to-interference >0. 5 (ref. 58) . Fold changes were corrected for isotope purity as described and adjusted for interference caused by coeluting nearly isobaric peaks, as estimated by the signal-to-interference measure 59 . Protein quantification was derived from individual spectra matching distinct peptides with a sum-based bootstrap algorithm; 95% confidence intervals were calculated for all protein fold-changes that were quantified with more than three spectra 57 .
For visualization, only proteins with ≥2 peptides and ≥3 spectra were considered in heat-map and scatter-plot representation (Fig. 1a,e) .
Coimmunoprecipitation. 4 × 10 7 MV4;11 or MOLM-13 cells were harvested. Cells were washed in ice-cold PBS and centrifuged at 400g for 5 min, 4 °C (twice) and lysed in 600 µL of modified HEPES lysis buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 5 mM MgCl 2 , 2 mM EGTA, 5% glycerol, 0.5% NP-40 (0.1% for wash buffer)) with protease-inhibitor-cocktail solution (Roche) for 2 min. Cell debris was precipitated by centrifugation at maximum speed (15,000 r.p.m.) for 10 min. A 100-µL sample was collected for western blot input control, before being diluted with 500 µL of 50 mM Tris buffer. 1 mL of supernatant was collected and split between two microcentrifuge tubes. 40 µL magnetic Dynabeads M-280 streptavidin (Invitrogen) was washed in HEPES lysis wash buffer (three times) and then incubated with lysates for 3 h at 4 °C on a spinning rotator (SB3, Stuart). After incubation, magnetic beads were precipitated with a Dyna Mag 2 magnet (Life Technologies). Samples were washed in modified HEPES wash lysis buffer (twice) with Dyna Mag 2 for bead separation; the final pellet was resuspended in 50 µL of wash lysis buffer. 10 µL of SDS sample buffer was added to bead-bound protein 'sample' solution, and 20 µL was added to the input sample and incubated at 95 °C for 5 min.
Immunoblotting. Whole cell lysates were mixed with Laemmli buffer, separated via SDS-PAGE and transferred to PVDF membranes (Millipore). Membranes were then sequentially incubated with primary antibodies (described below) and secondary antibodies conjugated with horseradish peroxidase (Invitrogen). Membranes were then incubated with ECL (GE Healthcare), and proteins were detected by exposure to X-ray film.
qRT-PCR. mRNA was prepared with a Qiagen RNeasy kit, and cDNA synthesis was performed with a SuperScript VILO kit (Life Technologies), per the manufacturers' instructions. Quantitative PCR analysis was performed on an Applied Biosystems StepOnePlus System with SYBR green reagents. For analysis of mouse cell-line samples, expression levels were determined with the ∆Ct method and normalized to β2 microglobulin and/or GAPDH. Assessment of expression changes associated with I-BET151 treatment occurred at 6 h after treatment with 500 nM I-BET151 and/or SGC0946 for 72-96 h. Sequences of primers are provided in the Supplementary Note. SGC0946 washout. Cells were cultured for 6, 8 or 10 h with SGC0946, after which the compound was washed out, and the medium was replaced with fresh medium. Cells were then cultured up to 72 h and harvested. Short-term treatment was performed on the same batch of cells just before harvesting.
Antibodies. The following antibodies were used in ChIP assays: anti-BRD4 (E2A7X, Cell Signaling), anti-H3K27ac (ab4729, Abcam), anti-H3K79me2 (ab3594, Abcam) and anti-RNA POL II (CTD4H8, Millipore). The following antibodies were used in immunoblotting assays: anti-BRD4 (A301-985A, Bethyl, and ab128874, Abcam) anti-HSP60 (sc-13966, Santa Cruz), anti-H3K79me2 (ab3594, Abcam), anti-MYC (9402S, Cell Signaling), anti-CDK9 (A303-492A, Bethyl), anti-LEO1 (A300-174A, Bethyl), anti-MLLT1 (A302-267A, Bethyl), anti-DOT1L (ab72454, Abcam), anti-IgG rabbit (Santa Cruz), anti-P300 (ab14984, Abcam), anti-H4K5ac (ab51997, Abcam) and anti-CREB1 (48H2, Cell Signaling). Validation is provided on the manufacturer's websites.
Pharmacokinetic optimization of SGC0946 delivery. The systemic exposure of SGC0946 was determined in 8-week-old male CD1 mice (n = 3 per dose route) after oral (PO), subcutaneous (SC) or intraperitoneal (IP) dosing at a target dose of 3 mg/kg (5 mL/kg) for all three routes. SGC0946 was suspended in 1% methylcellulose 400 (aq) or dissolved in 10% (w/v) Kleptose HPB for the PO and SC/IP dose groups, respectively. The systemic exposure of SGC0946 after insertion of a surgically implanted minipump was determined in 8-weekold male C57BL/6 mice (approximately 25 g, n = 3) at a target dose of 6 mg/kg/h (1 µL/h). SGC0946 was dissolved in 10% (w/v) Kleptose HPB to achieve a final concentration of 150 mg/mL. Serial blood samples (15 or 20 µL) were collected via the tail vein over the time-course. Blood samples were diluted with an equal volume of water and stored at approximately −20 °C before analysis by LC-MS/MS.
Blood samples were analyzed for SGC0946 with an analytical method based on protein precipitation and LC-MS/MS, using positive-ion electrospray ionization with an Phenomenex Kinetix C18 LC column and a Sciex API 4000 MS. Pharmacokinetic data analysis was performed with noncompartmental analysis in WinNonLin Phoenix v6.2 software.
Syngeneic mouse models of leukemia. Secondary syngeneic transplantation studies were performed with intravenous injection of 2 × 10 6 cells obtained from bone marrow or spleen into C57BL/6 male mice. All mice were 6-10 weeks old at the time of sublethal irradiation at a dose of 3 Gy. Treatment with vehicle, I-BET151, SGC0946 or both began at day 8. I-BET was administered via IP injection at 10 mg/kg/day on days 8, 9, 11,14 and 16. SGC0946 was administered via osmotic minipumps surgically implanted and filled with 150 mg/ml to deliver a dose of 6 mg/kg/h. Pumps were implanted at day 8 and left for the duration of the experiment. All mice were kept in a pathogen-free animal facility, inspected daily and sacrificed upon signs of distress and disease. All studies were conducted in accordance with the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals and were reviewed by the Institutional Animal Care and Use Committee at GSK or were conducted under the approval of the institutional animal ethics review board and were authorized by the Animal Experimentation Ethics Committee (AEEC), Peter MacCallum Cancer Centre. All mice were randomized before the commencement of experiment. Animal technicians were blinded to the experimental setup and outcome.
Inducible shRNA in vivo competition assay. Secondary MLL-AF9 cells were transduced with shScramble, shDOT1L, shBRD4 or both shDOT1l and shBRD4. Cells were sorted for BFP + , VENUS + or BFP + /VENUS + . Doxycycline was then added to cells in vitro for 48 h, and dsRED + cells were sorted and immediately
